Furthermore, metformin treatment suppressed angiogenesis-related gene expression by downregulating VEGFA, VEGFR2, and NRP1, which highlights its potential to target both apoptotic and angiogenic pathways in breast cancer. This evidence concerns the gene KDR and breast carcinoma.